<DOC>
	<DOCNO>NCT00495339</DOCNO>
	<brief_summary>Estimate clinical microbiological efficacy Levofloxacin ( Tavanic ) combine therapy MDR TB . Estimate safety Levofloxacin ( Tavanic ) combine therapy MDR TB .</brief_summary>
	<brief_title>MDR TB , Levofloxacin , Multi-Drug-Resistant Pulmonary Tuberculosis</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Tuberculosis , Multidrug-Resistant</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>Drugresistant pulmonary tuberculosis laboratory diagnose Known hypersensitivity levofloxacin , quinolones Patient epilepsy central nervous system diseases Renal insufficiency serum creatinine low 50 ml/min Arterial hypertension , ischemic heart disease acute phase Gastrointestinal disease , liver disease acute phase History drug alcohol abuse Patient history tendon disorder relate fluoroquinolone administration Pregnancy breastfeed woman Immune system disorder related chemotherapy , AIDS , long term administration corticosteroids The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>